Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at treatment for people with myeloma that has come back or stopped responding to treatment
Cancer type:
Blood cancers
Myeloma
Status:
Results
Phase:
Phase 2
This trial looked at bortezomib with or without siltuximab for myeloma. It was for people who’d already had treatment, but their myeloma had come back or started to get worse.
The trial was open in 18 countries for people to join between 2006 and 2009. The team published the results in 2015. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Doctors usually treat myeloma with chemotherapy, but sometimes treatment stops working or the myeloma comes back (relapses).
When this trial was done, doctors used bortezomib (Velcade) for people in this situation. Bortezomib is a type of targeted treatment called a proteasome inhibitor.
Researchers wanted to find out if having siltuximab (CNTO 328) as well as bortezomib was useful. Siltuximab is also a type of targeted treatment. It is a monoclonal antibody.
The people taking part in this trial were put into a treatment group at random:
- half had bortezomib and siltuximab
- half had bortezomib and a dummy drug (placebo)
The main aims of this trial were to find out:
- if siltuximab and bortezomib is a better treatment than bortezomib alone
- more about side effects
- how the treatments affect people’s quality of life
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma
R Z Orlowski and others
The American Journal of Hematology, 2015. Volume 90, issue 1, pages 42 - 49.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Professor Gareth Morgan
Supported by
Experimental Cancer Medicine Centre (ECMC)
Global Clinical Operations (Division of Janssen-Cilag Ltd) representing Centocor B.V.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
2970
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Around 1 in 5 people take part in clinical trials
